Cargando…
RNA modification in cardiovascular disease: implications for therapeutic interventions
Cardiovascular disease (CVD) is the leading cause of death in the world, with a high incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable in cell, maintaining cell homeostasis and function by dynamically regulating gene expression. Accumulating evidence has revea...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603151/ https://www.ncbi.nlm.nih.gov/pubmed/37884527 http://dx.doi.org/10.1038/s41392-023-01638-7 |
_version_ | 1785126543281881088 |
---|---|
author | Wang, Cong Hou, Xuyang Guan, Qing Zhou, Huiling Zhou, Li Liu, Lijun Liu, Jijia Li, Feng Li, Wei Liu, Haidan |
author_facet | Wang, Cong Hou, Xuyang Guan, Qing Zhou, Huiling Zhou, Li Liu, Lijun Liu, Jijia Li, Feng Li, Wei Liu, Haidan |
author_sort | Wang, Cong |
collection | PubMed |
description | Cardiovascular disease (CVD) is the leading cause of death in the world, with a high incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable in cell, maintaining cell homeostasis and function by dynamically regulating gene expression. Accumulating evidence has revealed the role of aberrant gene expression in CVD caused by dysregulated RNA modification. In this review, we focus on nine common RNA modifications: N(6)-methyladenosine (m(6)A), N(1)-methyladenosine (m(1)A), 5-methylcytosine (m(5)C), N(7)-methylguanosine (m(7)G), N(4)-acetylcytosine (ac(4)C), pseudouridine (Ψ), uridylation, adenosine-to-inosine (A-to-I) RNA editing, and modifications of U34 on tRNA wobble. We summarize the key regulators of RNA modification and their effects on gene expression, such as RNA splicing, maturation, transport, stability, and translation. Then, based on the classification of CVD, the mechanisms by which the disease occurs and progresses through RNA modifications are discussed. Potential therapeutic strategies, such as gene therapy, are reviewed based on these mechanisms. Herein, some of the CVD (such as stroke and peripheral vascular disease) are not included due to the limited availability of literature. Finally, the prospective applications and challenges of RNA modification in CVD are discussed for the purpose of facilitating clinical translation. Moreover, we look forward to more studies exploring the mechanisms and roles of RNA modification in CVD in the future, as there are substantial uncultivated areas to be explored. |
format | Online Article Text |
id | pubmed-10603151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106031512023-10-28 RNA modification in cardiovascular disease: implications for therapeutic interventions Wang, Cong Hou, Xuyang Guan, Qing Zhou, Huiling Zhou, Li Liu, Lijun Liu, Jijia Li, Feng Li, Wei Liu, Haidan Signal Transduct Target Ther Review Article Cardiovascular disease (CVD) is the leading cause of death in the world, with a high incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable in cell, maintaining cell homeostasis and function by dynamically regulating gene expression. Accumulating evidence has revealed the role of aberrant gene expression in CVD caused by dysregulated RNA modification. In this review, we focus on nine common RNA modifications: N(6)-methyladenosine (m(6)A), N(1)-methyladenosine (m(1)A), 5-methylcytosine (m(5)C), N(7)-methylguanosine (m(7)G), N(4)-acetylcytosine (ac(4)C), pseudouridine (Ψ), uridylation, adenosine-to-inosine (A-to-I) RNA editing, and modifications of U34 on tRNA wobble. We summarize the key regulators of RNA modification and their effects on gene expression, such as RNA splicing, maturation, transport, stability, and translation. Then, based on the classification of CVD, the mechanisms by which the disease occurs and progresses through RNA modifications are discussed. Potential therapeutic strategies, such as gene therapy, are reviewed based on these mechanisms. Herein, some of the CVD (such as stroke and peripheral vascular disease) are not included due to the limited availability of literature. Finally, the prospective applications and challenges of RNA modification in CVD are discussed for the purpose of facilitating clinical translation. Moreover, we look forward to more studies exploring the mechanisms and roles of RNA modification in CVD in the future, as there are substantial uncultivated areas to be explored. Nature Publishing Group UK 2023-10-27 /pmc/articles/PMC10603151/ /pubmed/37884527 http://dx.doi.org/10.1038/s41392-023-01638-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Wang, Cong Hou, Xuyang Guan, Qing Zhou, Huiling Zhou, Li Liu, Lijun Liu, Jijia Li, Feng Li, Wei Liu, Haidan RNA modification in cardiovascular disease: implications for therapeutic interventions |
title | RNA modification in cardiovascular disease: implications for therapeutic interventions |
title_full | RNA modification in cardiovascular disease: implications for therapeutic interventions |
title_fullStr | RNA modification in cardiovascular disease: implications for therapeutic interventions |
title_full_unstemmed | RNA modification in cardiovascular disease: implications for therapeutic interventions |
title_short | RNA modification in cardiovascular disease: implications for therapeutic interventions |
title_sort | rna modification in cardiovascular disease: implications for therapeutic interventions |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603151/ https://www.ncbi.nlm.nih.gov/pubmed/37884527 http://dx.doi.org/10.1038/s41392-023-01638-7 |
work_keys_str_mv | AT wangcong rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT houxuyang rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT guanqing rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT zhouhuiling rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT zhouli rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT liulijun rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT liujijia rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT lifeng rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT liwei rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions AT liuhaidan rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions |